These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6728999)

  • 1. The dyskinesia identification system--Coldwater (DIS-Co): a tardive dyskinesia rating scale for the developmentally disabled.
    Sprague RL; Kalachnik JE; Breuning SE; Davis VJ; Ullmann RK; Cullari S; Davidson NA; Ferguson DG; Hoffner BA
    Psychopharmacol Bull; 1984; 20(2):328-38. PubMed ID: 6728999
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychometric properties of the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Sprague RL; Kalachnik JE; Slaw KM
    Ment Retard; 1989 Jun; 27(3):141-8. PubMed ID: 2739567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of tardive dyskinesia as measured on the Dyskinesia Identification System--Coldwater.
    Bostrom AC; Walker MK
    Nurs Res; 1990; 39(5):274-9. PubMed ID: 2399131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dyskinetic movement disorder among adults with mental retardation: phenomenology and co-occurrence with stereotypy.
    Bodfish JW; Newell KM; Sprague RL; Harper VN; Lewis MH
    Am J Ment Retard; 1996 Sep; 101(2):118-29. PubMed ID: 8883667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The convergent and divergent validity of the Matson Evaluation of Drug Side-effects (MEDS) and the Dyskinesia Identification System: Condensed User Scale (DISCUS).
    Matson JL; Fodstad JC; Rivet TT
    J Intellect Dev Disabil; 2008 Dec; 33(4):337-44. PubMed ID: 19039694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Number of nonassessable items and Cooperation level of the retarded during systematic dyskinesia examinations.
    Kalachnik JE; Kidd-Nielsen P; Harder SR
    Psychopharmacol Bull; 1983; 19(1):16-9. PubMed ID: 6828620
    [No Abstract]   [Full Text] [Related]  

  • 7. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia in mentally retarded children, adolescents, and young adults: North Carolina and Michigan studies.
    Gualtieri CT; Breuning SE; Schroeder SR; Quade D
    Psychopharmacol Bull; 1982 Jan; 18(1):62-5. PubMed ID: 6152872
    [No Abstract]   [Full Text] [Related]  

  • 10. Arm tremor, tardive dyskinesia, and mental retardation.
    van Emmerik RE; Sprague RL; Newell KM
    Am J Ment Retard; 1993 Jul; 98(1):74-83. PubMed ID: 8103999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin E in the treatment of tardive dyskinesia.
    Akhtar S; Jajor TR; Kumar S
    J Postgrad Med; 1993; 39(3):124-6. PubMed ID: 7914238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic investigation of tardive dyskinesia in inpatients.
    Smith JM; Kucharski LT; Oswald WT; Waterman LJ
    Am J Psychiatry; 1979 Jul; 136(7):918-22. PubMed ID: 453354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of tardive dyskinesia by single and repeated application of 7-methoxytacrin.
    Hanus H; Tůtma I; Zapletálek M; Fusek J; Hrdina V
    Homeost Health Dis; 1991; 33(5-6):301-4. PubMed ID: 18265509
    [No Abstract]   [Full Text] [Related]  

  • 15. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability, validity, and a total score cutoff for the dyskinesia identification system: condensed user scale (DISCUS) with mentally ill and mentally retarded populations.
    Sprague RL; Kalachnik JE
    Psychopharmacol Bull; 1991; 27(1):51-8. PubMed ID: 1862206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and treatment of tardive dyskinesia (author's transl)].
    Shen YC
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1979; 12(1):11-3. PubMed ID: 551864
    [No Abstract]   [Full Text] [Related]  

  • 19. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric properties of ADHD rating scales among children with mental retardation.
    Miller ML; Fee VE; Jones CJ
    Res Dev Disabil; 2004; 25(5):477-92. PubMed ID: 15217675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.